| pegylated liposomal doxorubicin / Generic mfg. |
NCT00653952: CAELYX Versus Paclitaxel HCl in Patients With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy |
|
|
| Terminated | 3 | 220 | US | CAELYX, Paclitaxel HCl | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Sequus Pharmaceuticals, ALZA | Ovarian Neoplasms | | 04/00 | | |
NCT00191607: A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer. |
|
|
| Completed | 3 | 162 | US | Gemcitabine, liposomal doxorubicin | Eli Lilly and Company | Genital Neoplasms, Female, Fallopian Tube Neoplasms, Ovarian Neoplasms, Pelvic Neoplasms, Peritoneal Neoplasms | | 11/05 | | |
NCT00057720: TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer |
|
|
| Completed | 3 | 440 | Europe, US, RoW | TLK286 HCl for injection, topotecan hydrochloride for injection, doxorubicin HCl liposome injection | Telik | Ovarian Neoplasms | 12/06 | 12/06 | | |
NCT00043082: S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer |
|
|
| Completed | 3 | 61 | US | carboplatin, pegylated liposomal doxorubicin hydrochloride | Southwest Oncology Group, National Cancer Institute (NCI) | Ovarian Cancer, Peritoneal Cavity Cancer | 06/07 | 07/11 | | |
NCT00245050: Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer |
|
|
| Completed | 3 | 34 | US | pyridoxine hydrochloride, Placebo, doxorubicin HCL liposome | Case Comprehensive Cancer Center, National Cancer Institute (NCI) | Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer | 04/08 | 09/11 | | |
NCT00102973: TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer |
|
|
| Completed | 3 | 244 | US | TLK286 in Combination with Carboplatin, Doxorubicin HCl Liposome Injection | Telik | Ovarian Neoplasms | 07/08 | 07/08 | | |
| Terminated | 3 | 244 | US, Europe, RoW | Telcyta, TLK286, canfosfamide, Liposomal Doxorubicin, Doxil, Caelyx | Telik | Ovarian Neoplasms | 12/08 | 12/08 | | |
CALYPSO, NCT00189553: Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse |
|
|
| Completed | 3 | 976 | Europe | Pegylated liposomal doxorubicin, Caelyx, Carboplatin, generic drug, Paclitaxel | ARCAGY/ GINECO GROUP, Schering-Plough, Arbeitsgemeinschaft Gynaekologische Onkologie Austria, AGO Study Group, Australia New Zealand Gynaecological Oncology Group, European Organisation for Research and Treatment of Cancer - EORTC, NCIC Clinical Trials Group, NSGO | Ovarian Cancer, Fallopian Tube Cancer | 01/09 | 06/12 | | |
NCT00011986: Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer |
|
|
| Completed | 3 | 4312 | US | Paclitaxel, Anzatax, TAX, Carboplatin, Gemcitabine Hydrochloride, dFdC, dFdCyd, Pegylated Liposomal Doxorubicin Hydrochloride, doxorubicin HCl liposome, TLC D-99, Topotecan Hydrochloride, Hycamtin, SKF S-104864-A, TOPO, Therapeutic Conventional Surgery | Gynecologic Oncology Group, Southwest Oncology Group, Medical Research Council, National Cancer Institute (NCI) | Primary Peritoneal Carcinoma, Stage III Ovarian Cancer, Stage IV Ovarian Cancer | 03/10 | 01/13 | | |
| Completed | 3 | 672 | US, Canada, Europe, RoW | Trabectedin, Yondelis, DOXIL, CAELYX, Dexamethasone | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., PharmaMar | Ovarian Cancer | 11/10 | 11/10 | | |
NCT00538603: Multi-national, Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin (CAELYX) and Carboplatin vs. Paclitaxel and Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse. (CALYPSO) |
|
|
| Completed | 3 | 8 | US | pegylated liposomal Doxorubicin (CAELYX) & Carboplatin, Paclitaxel & Carboplatin | King Faisal Specialist Hospital & Research Center | Epithelial Ovarian Cancer | 06/13 | 06/13 | | |
NCT01840943: A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy |
|
|
| Terminated | 3 | 32 | RoW | CAELYX, Topotecan HCl | Xian-Janssen Pharmaceutical Ltd. | Epithelial Ovarian Cancer | 05/14 | 08/14 | | |
| Terminated | 3 | 223 | US, Canada, Europe, RoW | AMG386 plus PLD, Placebo plus PLD | Amgen | Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer | 08/14 | 04/17 | | |
|
NCT01846611 / 2012-004808-34: A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
|
|
| Completed | 3 | 581 | US, Europe, RoW | Trabectedin, DOXIL, Dexamethasone | Janssen Research & Development, LLC, PharmaMar | Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms | 01/18 | 11/18 | | |
